National Institutes of Health (NIH) Funds Major Chromium Picolinate and Type 2 Diabetes Research Study

PURCHASE, NY, September 9, 2003 -- The National Institutes of Health (NIH) awarded Dr. William Cefalu, at the prestigious Pennington Biomedical Research Center of Louisiana State University, a substantial research grant to evaluate the use of Chromax® chromium picolinate supplementation in people with type 2 diabetes. This landmark study will make a critical contribution to the existing body of clinical evidence demonstrating the importance of chromium picolinate in the management of diabetes, a disease that affects 194 million people worldwide.

Dr. Cefalu states, "This study will use 'gold standard' techniques to evaluate carbohydrate metabolism in human subjects with type 2 diabetes and will also use techniques to evaluate the specific mechanism by which it may work. Based on the large numbers of subjects to be evaluated, this study has the potential to specifically address the role of chromium picolinate in diabetes, and follow-up on the positive observations seen in the obese animal models." There are currently 13 published human clinical studies demonstrating significant efficacy with chromium picolinate supplementation in diabetes and metabolic syndrome.

Nutrition 21's (Nasdaq: NXXI) Chromax chromium picolinate has been selected as the form of chromium for this landmark study. Gail Montgomery, President and CEO, Nutrition 21, Inc. comments, “This is great news for millions of people with diabetes who can potentially benefit from chromium picolinate supplementation as a low-cost, safe, and effective nutritional therapy. The significant investment by the NIH in chromium picolinate research complements, and is expected to further validate, our own aggressive research and development program. In keeping with Nutrition 21’s business strategy, we expect government participation to help facilitate our near-term objective of securing Food and Drug Administration (FDA) approved health claims for our products. More importantly, this should accelerate the ultimate goal of having Nutrition 21’s proprietary chromium technologies, like Diachrome®, incorporated in standard health plan treatment protocols for people with diabetes.

Nutrition 21 is a leading developer and provider of nutritional products, whose health benefits are substantiated by clinical research. The Company markets Chromax chromium picolinate, the leading brand of chromium, and holds 35 patents for nutrition products, 22 for chromium compounds and their uses. More information is available at More information about Chromax is available at and Diachrome at

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.